Urology treats urinary tract diseases in all genders and male reproductive issues, covering the kidneys, bladder, prostate, urethra, from infections to complex cancers.
Send us all your questions or requests, and our expert team will assist you.
Ureteral tumors are a unique and complex type of cancer that develop in the upper urinary tract. The ureter is lined with a special tissue called urothelium, which also lines the kidney’s drainage system, the bladder, and part of the urethra. Because of this, tumors in the ureter are called Upper Tract Urothelial Carcinomas. Although they come from the same type of cells as bladder cancer, ureteral tumors have their own genetic and physical features due to how they develop and their exposure to concentrated urine.
Ureteral tumors can be either benign or cancerous, but cancerous types are much more common. The main type is urothelial carcinoma, which used to be called transitional cell carcinoma. These cancers start when the lining cells of the ureter change and lose their normal controls on growth and cell death. This process is often linked to the ‘field effect,’ meaning the entire lining from the kidney to the bladder can be at risk for cancer because it is exposed to cancer-causing substances in the urine. This is why these tumors often show up in more than one place in the urinary tract, either at the same time or over time.
Ureteral tumors can block the narrow tube of the ureter. The ureter moves urine from the kidney to the bladder. Even a small tumor can cause urine to back up, leading to swelling of the kidney (hydronephrosis) and higher pressure inside the tube. This blockage is serious because, if it lasts too long, it can damage the kidney.
Classifying ureteral tumors is important for predicting outcomes and choosing treatment. Most are urothelial carcinomas, but some are squamous cell carcinomas (often linked to long-term irritation or infection) or rare adenocarcinomas. Urothelial carcinomas are divided by grade and stage. Low-grade tumors usually grow as finger-like projections and are slow-growing but often come back. High-grade tumors are more aggressive, often flat, and can invade deeper layers of the ureter.
The ureter has a thinner muscle wall than the bladder, so high-grade ureteral tumors can spread more easily and quickly to other parts of the body. Research is now focusing on the genetic changes in these cancers, like mutations in FGFR3 or TP53, which help tell low-grade from high-grade tumors. Knowing these genetic details is changing how doctors define and treat the disease, allowing for more targeted and personalized treatments.
Studying ureteral tumors in regenerative medicine shows how flexible the urothelium can be. Normally, this tissue acts as a barrier and can repair itself after injury. In cancer, though, this repair process goes wrong, often because of long-term inflammation or toxins, leading to uncontrolled cell growth. Researchers think that some tumors may start from special cancer stem cells found in the deepest layer of the urothelium.
These cancer stem cells can renew themselves and help tumors grow, and they are often resistant to standard chemotherapy. Finding ways to target these cells is a new area in cancer treatment. Regenerative medicine is also important in surgery for these tumors. When part of the ureter is removed, doctors need to rebuild the urinary tract. New techniques use special scaffolds with the patient’s own cells to create new ureter segments, which may help avoid using bowel tissue for reconstruction.
Ureteral tumors are rare, making up only five to ten percent of all urothelial cancers. Because they are uncommon, it is harder to track them and set standard treatments worldwide. In Western countries, about one or two people per 100,000 get upper tract urothelial carcinoma each year. However, some places, like the Balkans and Taiwan, have much higher rates. This is often due to environmental toxins, such as aristolochic acid from certain plants used in traditional medicine or found in contaminated wheat.
In these regions, ureteral tumors are often caused by environmental toxins rather than happening by chance. Most people who get this cancer are older adults, usually in their 60s or 70s, and men are affected twice as often as women. However, some younger people with inherited conditions like Lynch syndrome are also at risk. Knowing these patterns helps doctors decide who should be screened and how to catch the disease early.
Although ‘ureteral tumor’ usually means cancer, non-cancerous growths can also develop in the ureter. The most common benign type is the fibroepithelial polyp, which is made of soft tissue covered by normal lining. These polyps are usually long and thin, and while they can block the ureter, they do not invade like cancer. Other rare benign tumors include leiomyomas (from muscle) and inverted papillomas.
Differentiating these benign entities from malignant carcinomas is a critical diagnostic challenge, often requiring direct endoscopic visualization and biopsy. The existence of these benign forms underscores the importance of precise tissue characterization to avoid unnecessary radical surgeries such as nephroureterectomy, which involves the removal of the kidney and ureter, for non-cancerous conditions.
Send us all your questions or requests, and our expert team will assist you.
Kidney cancer, or renal cell carcinoma, arises from the filtration cells of the kidney parenchyma itself. A ureteral tumor, or upper tract urothelial carcinoma, arises from the lining of the drainage system, specifically the renal pelvis and ureter. They are biologically different cancers with different causes, behaviors, and treatments, even though they both affect the upper urinary tract.
No, not all ureteral tumors are cancerous. While malignant urothelial carcinoma is the most common type, benign tumors such as fibroepithelial polyps or leiomyomas can occur. However, because malignant tumors are more common and dangerous, any mass in the ureter is treated with high suspicion until a biopsy confirms it is benign.
The field effect, or field cancerization, refers to the concept that the entire lining of the urinary tract, including the kidney, ureter, and bladder, has been exposed to the same carcinogens in the urine. Therefore, the entire lining is at risk. This explains why patients with a ureteral tumor are at high risk for developing separate tumors in the bladder or the other kidney over time.
The surface area of the ureter is much smaller than that of the bladder. Additionally, urine flows rapidly through the ureter, whereas it is stored in the bladder for hours. This storage allows carcinogens in the urine to have prolonged contact with the bladder lining, increasing the risk of mutation there compared to the ureteral transit-only zone.
Yes, there is a strong genetic link in some cases. Lynch syndrome is an inherited genetic condition that impairs the body’s ability to repair errors in DNA replication. This leads to a high risk of developing various cancers, including colon cancer and upper tract urothelial cancer. Patients with a family history of these cancers may need genetic screening.
Your Comparison List (you must select at least 2 packages)
